Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | LSS | P48449 | 2/20 | 0.44 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5483237 | 0.91 | EPHB4 (0.45) | HPGDRAB9ANPC1EPHB4KMT2A | |
| SCHEMBL5479137 | 0.78 | AURKA (0.59) | HPGD | |
| SCHEMBL1068623 | 0.76 | HPGD (0.52) | HPGDALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL5480118 | 0.76 | EPHB4 (0.63) | HPGDALDH1A1MAPTRAB9AEPHB4 | |
| SCHEMBL5478272 | 0.74 | EPHB4 (0.58) | MAPTEPHB4 | |
| SCHEMBL5482760 | 0.73 | EPHB4 (0.70) | EPHB4 | |
| SCHEMBL5478249 | 0.73 | EPHB4 (0.61) | HPGDALDH1A1MAPTRAB9AEPHB4 | |
| SCHEMBL5477405 | 0.72 | EPHB4 (0.69) | EPHB4 | |
| SCHEMBL5482855 | 0.71 | EPHB4 (0.65) | EPHB4 | |
| SCHEMBL5482755 | 0.71 | EPHB4 (0.59) | LSSEPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312341-B2 | 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | claimed |
| US-20040067951-A1 | 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof | GILEAD CONNECTICUT, INC. | 2004-04-08 | — | — | US | claimed |
| WO-2004022562-A1 | 6-ARYL-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CELLULAR GENOMICS, INC. (US) | 2004-03-18 | — | — | WO | claimed |
| US-7312341-B2 | 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20040067951-A1 | 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof | GILEAD CONNECTICUT, INC. | 2004-04-08 | — | — | US | disclosed |
| WO-2004022562-A1 | 6-ARYL-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CELLULAR GENOMICS, INC. (US) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067951-A1 | 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof | MAP3K8, PRKACA, MAP3K1 | HPGD 1671/4885ALDH1A1 1146/4885MAPT 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.